Risks of Venous Thromboembolic Events and the Great Obstetric Syndromes
https://doi.org/10.31550/1727-2378-2023-22-1-33-39
Abstract
Aim: Based on the study of the history, course of pregnancy and childbirth, to assess the risks of venous thromboembolic events among women with major obstetric syndromes.
Design: Retrospective cohort study using the continuum sampling method.
Materials and methods. 200 birth histories were analyzed: group 1 — 55 women with great obstetric syndromes, group 2 — 145 pregnant without them. The history of women, pregnancy outcomes were studied, and an analysis of the risks of venous thromboembolic complications was carried out.
Results. Anamnestic risk factors for major obstetric syndromes were a family history aggravated by early thromboembolic events (RR = 3,13; 95% CI: 1,34–7,30), unemployed status (RR = 1,73; 95% CI: 1,32–2,65), preeclampsia in the past (RR = 23,46; 95% CI: 1,28–428,80), first pregnancy (RR = 1,63; 95% CI: 1,04–2,55), chronic arterial hypertension (RR = 8,45; 95% CI: 1,76–40,66). There was a significant increase in the risk of venous thromboembolic complications in patients of group 1 during pregnancy (1 (1–2) points; p < 0.001) and in the postpartum period (3 (1–4) points; p < 0.001).
Conclusion. Prognostic markers of great obstetric syndromes were aggravated family and personal obstetric anamnesis, parity, low social status, chronic arterial hypertension. A significant increase in the risk of venous thromboembolic complications in pregnant women and puerperas with major obstetric syndromes was revealed.
About the Authors
V. F. Dolgushina
South-Ural State Medical University
Russian Federation
Russian Federation
64 Vorovskoy Str., Chelyabinsk, 454092
E. G. Syundyukova
South-Ural State Medical University
Russian Federation
Russian Federation
64 Vorovskoy Str., Chelyabinsk, 454092
V. S. Chulkov
South-Ural State Medical University
Russian Federation
Russian Federation
64 Vorovskoy Str., Chelyabinsk, 454092
K. A. Unigovskaya
South-Ural State Medical University
Russian Federation
Russian Federation
64 Vorovskoy Str., Chelyabinsk, 454092
References
1. Di Renzo G.C. The great obstetrical syndromes. J. Matern. Fetal Neonatal Med. 2009;22(8):633–5. DOI: 10.1080/14767050902866804
2. Romero R. Prenatal medicine: the child is the father of the man. J. Matern. Fetal Neonatal Med. 2009;22(8):636–9. DOI: 10.1080/14767050902784171
3. Vereina N.K., Dolgushina V.F., Fartunina Y.V., Kolyada E.V. Hemostasis changes in pregnant women with fetal growth retardation. Thrombosis, Hemostasis and Rheology. 2020;3:55–61. (in Russian). DOI: 10.25555/THR.2020.3.0929
4. Kovalev V.V., Kudryavtseva E.V. Molecular genetic deviations and obstetric pathology. Obstetrics and Gynecology. 2020;1:26–32. (in Russian). DOI: 10.18565/aig.2020.1.26-32
5. Brosens I., Puttemans P., Benagiano G. Placental bed research: I. The placental bed: from spiral arteries remodeling to the great obstetrical syndromes. Am. J. Obstet. Gynecol. 2019;221(5):437–56. DOI: 10.1016/j.ajog.2019.05.044
6. Zur R.L., Kingdom J.C., Parks W.T., Hobson S.R. The placental basis of fetal growth restriction. Obstet. Gynecol. Clin. North Am. 2020;47(1):81–98. DOI: 10.1016/j.ogc.2019.10.008
7. Staff A.C. The two-stage placental model of preeclampsia: an update. J. Reprod. Immunol. 2019;134–135:1–10. DOI: 10.1016/j.jri.2019.07.004
8. Greer I.A., Aharon A., Brenner B., Gris J.C. Coagulation and placenta-mediated complications. Rambam Maimonides Med. J. 2014;5(4):e0034. DOI: 10.5041/RMMJ.10168
9. Gris J.C., Bouvier S., Cochery-Nouvellon É., Mercier É. et al. The role of haemostasis in placenta-mediated complications. Thromb. Res. 2019;181(1):10–14. DOI: 10.1016/S0049-3848(19)30359-7
10. Say L., Chou D., Gemmill A., Tunçalp Ö. et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob. Health. 2014;2(6):e323–33. DOI: 10.1016/S2214-109X(14)70227-X
11. Bates S.M., Greer I.A., Middeldorp S., Veenstra D.L. et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:691-736. DOI: 10.1378/chest.11-2300
12. O'Shaughnessy F., O'Reilly D., Ní Áinle F. Current opinion and emerging trends on the treatment, diagnosis, and prevention of pregnancy-associated venous thromboembolic disease: a review. Transl. Res. 2020;225:20–32. DOI: 10.1016/j.trsl.2020.06.004
13. Knight M., Nair M., Brocklehurst P., Kenyon S. et al. Examining the impact of introducing ICD-MM on observed trends in maternal mortality rates in the UK 2003–13. BMC Pregnancy Childbirth. 2016;16(1):178. DOI: 10.1186/s12884-016-0959-z
14. Crowley M.P., Noone C., Higgins J.R., O'Shea S. A multicentre study of thromboprophylaxis in pregnancy. Ir. Med. J. 2017;110(5):567.
15. Akinshina S., Makatsariya A., Bitsadze V., Khizroeva J. et al. Thromboprophylaxis in pregnant women with thrombophilia and a history of thrombosis. J. Perinat. Med. 2018;46(8):893–9. DOI: 10.1515/jpm-2017-0329
16. Iseyemi A., Zhao Q., McNicholas C., Peipert J.F. Socioeconomic status as a risk factor for unintended pregnancy in the contraceptive CHOICE Project. Obstet. Gynecol. 2017;130(3):609–15. DOI: 10.1097/AOG.0000000000002189
17. Syundyukova E.G., Chulkov V.S., Ryabikina M.G. Preeclampsia: the current state of problem. Doctor.Ru. 2021;20(1):11–16. (in Russian). DOI: 10.31550/1727-2378-2021-20-1-11-16
18. Kalafat E., Laoreti A., Khalil A., Da Silva Costa F. et al. Ophthalmic artery Doppler for prediction of pre-eclampsia: systematic review and meta-analysis. Ultrasound Obstet. Gynecol. 2018;51(6):731–7. DOI: 10.1002/uog.19002
19. Lipatov I.S., Tezikov Yu.V., Azamatov A.R., Shmakov R.G. Identity of preeclampsia and metabolic syndrome clinical manifestations: searching for substantiation. Obstetrics and Gynecology. 2021;3:81–9. (in Russian). DOI: 10.18565/aig.2021.3.81-89
20. Medvedev B.I., Syundyukova E.G., Sashenkov S.L., Naimushina Yu.V. A clinical, laboratory and instrumental model for the early prognosis of preeclampsia. Russian Bulletin of Obstetrician-Gynecologist. 2019;19(1):12-17. (in Russian). DOI: 10.17116/rosakush20191901112
21. Loussert L., Vidal F., Parant O., Hamdi S.M. et al. Aspirin for prevention of preeclampsia and fetal growth restriction. Prenat. Diagn. 2020;40(5):519–27. DOI: 10.1002/pd.5645
22. Haddad B., Lecarpentier E., Touboul C., Sibai B.M. Low-molecular-weight heparin for the prevention of placenta-mediated pregnancy complications. Clin. Obstet. Gynecol. 2017;60(1):153–60. DOI: 10.1097/GRF.0000000000000252
23. The committee of experts of the Russian Society of Cardiology (RSC). Section of cardiovascular diseases in pregnant women. National guidelines for diagnosis and treatment of cardiovascular diseases during pregnancy 2018. New revision: July, 2018. Russian Journal of Cardiology. 2018;7:156-200. (in Russian). DOI: 10.15829/1560-4071-2018-7-156-200
24. Duffy J.M.N., Cairns A.E., Magee L.A., von Dadelszen P. et al. Standardising definitions for the pre-eclampsia core outcome set: a consensus development study. Pregnancy Hypertens. 2020;21:208–217. DOI: 10.1016/j.preghy.2020.06.005
25. Khodzhaeva Z.S., Kholin A.M., Chulkov V.S., Muminova K.T. Aspirin in the prevention of preeclampsia and associated maternal and perinatal complications. Obstetrics and Gynecology. 2018;8:12–18. (in Russian). DOI: 10.18565/aig.2018.8.12-18
26. Boutin A., Gasse C., Guerby P., Giguère Y. et al. First-trimester preterm preeclampsia screening in nulliparous women: the great obstetrical syndrome (GOS) study. J. Obstet. Gynaecol. Can. 2021;43(1):43–9. DOI: 10.1016/j.jogc.2020.06.011
Review
For citations:
Dolgushina V.F., Syundyukova E.G., Chulkov V.S., Unigovskaya K.A. Risks of Venous Thromboembolic Events and the Great Obstetric Syndromes. Title. 2023;22(1):33-39. (In Russ.) https://doi.org/10.31550/1727-2378-2023-22-1-33-39
Views:
12
Email this article 